Literature DB >> 12419759

Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase.

A Vora, M Bhutani, A Sharma, V Raina.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12419759     DOI： 10.1093/annonc/mdf304

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

1.  Tumor Lysis Syndrome in the Chronic Phase of Chronic Myeloid Leukemia Following COVID-19 Infection: A Case Report.

Authors:  Adnan Humam Waseem Hajjar; Shahem Abbarh; Abdulrahman Al-Mashdali; Awni Alshurafa; Mohammad Abu-Tineh; Hana Qasim; Khalid Ahmed; Mohamed A Yassin
Journal:  Cureus       Date:  2022-04-22

Review 2.  Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.

Authors:  Lisa Cammalleri; Mariano Malaguarnera
Journal:  Int J Med Sci       Date:  2007-03-02       Impact factor: 3.738

3.  Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571).

Authors:  Elizabeth M Pinder; Gurprit S S Atwal; Abraham A Ayantunde; Sarah Khan; Mike Sokal; Tom McCulloch; Simon L Parsons
Journal:  Sarcoma       Date:  2007

4.  Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Authors:  Musa Yilmaz; Amit Lahoti; Susan O'Brien; Graciela M Nogueras-González; Jan Burger; Alessandra Ferrajoli; Gautam Borthakur; Farhad Ravandi; Sherry Pierce; Elias Jabbour; Hagop Kantarjian; Jorge E Cortes
Journal:  Cancer       Date:  2015-07-28       Impact factor: 6.860
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.